Destiny Pharma (LON:DEST) Trading Down 30.1% – What’s Next?

Destiny Pharma plc (LON:DEST)’s stock price traded down 30.1% during mid-day trading on Wednesday . The company traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). 4,179,453 shares were traded during mid-day trading, an increase of 484% from the average session volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.06).

Analyst Upgrades and Downgrades

Separately, Shore Capital reiterated a “house stock” rating on shares of Destiny Pharma in a research report on Monday, July 15th.

Destiny Pharma Price Performance

The stock’s fifty day moving average price is GBX 3.04 and its 200-day moving average price is GBX 10.44. The firm has a market cap of £2.87 million, a PE ratio of -50.00 and a beta of 0.22.

Insider Buying and Selling

In related news, insider Nigel Rudd bought 1,240,000 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was acquired at an average cost of GBX 0.25 ($0.00) per share, with a total value of £3,100 ($4,048.05). 25.94% of the stock is currently owned by company insiders.

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.